DETERMINATION OF THE SAFETY AND EFFECTIVENESS OF CARBOXYTHERAPY IN IN VIVO MODELS OF OSTEOARTHRITIS AND TENDON INFLAMMATION
DOI:
https://doi.org/10.15674/0030-598720254108-114Keywords:
Carboxytherapy, CO2, inflammation, osteoarthritis, cytokines, rats, degenerative joint diseases, degenerative-inflammatory conditionsAbstract
Local administration of carbon dioxide (carboxytherapy) is regarded as a promising approach for modulating inflammation, improving microcirculation, and stimulating reparative processes. However, traditional subcutaneous CO2 delivery techniques are associated with variability of local effects, risk of mechanical tissue irritation, and insufficient standardization of administration parameters, which limits reproducibility of experimental findings. These limitations highlight the need to develop optimized CO2 delivery techniques with controlled administration and improved safety. Objective. To evaluate the efficacy and safety of subcutaneous administration of a CO2 + NaHCO3 gas-buffer mixture in preclinical models of acute inflammation and monoiodoacetate (MIA)-induced osteoarthritis. Methods. The study was conducted in rats using formalin- and carrageenaninduced models of acute inflammation and a monoiodoacetic acid–induced osteoarthritis model. Animals received subcutaneous injections of a CO2 + NaHCO3 mixture (1:1) in small volumes; comparisons were performed against the classical subcutaneous CO2 administration protocol described by Raymundo et al. Results. In acute inflammation models, administration of the CO2 + NaHCO3 mixture significantly reduced edema severity (p < 0.001). In the MIA-induced osteoarthritis model, treatment resulted in a statistically significant decrease in TNF-α and IL-6 levels and an increase in TGF-β1 concentration (all p < 0.001), indicating anti-inflammatory activity and modulatory effects on systemic inflammatory markers. Conclusions. The subcutaneous administration technique of the CO2 + NaHCO3 mixture investigated in this study demonstrated anti-inflammatory activity and a favorable safety profile in preclinical models, supporting the rationale for further research into its potential application for degenerative-inflammatory disorders of the musculoskeletal system.
Downloads
How to Cite
Issue
Section
License
Copyright (c) 2025 Viktor Shtroblia, Ruslan Lutsenko

This work is licensed under a Creative Commons Attribution 4.0 International License.
The authors retain the right of authorship of their manuscript and pass the journal the right of the first publication of this article, which automatically become available from the date of publication under the terms of Creative Commons Attribution License, which allows others to freely distribute the published manuscript with mandatory linking to authors of the original research and the first publication of this one in this journal.
Authors have the right to enter into a separate supplemental agreement on the additional non-exclusive distribution of manuscript in the form in which it was published by the journal (i.e. to put work in electronic storage of an institution or publish as a part of the book) while maintaining the reference to the first publication of the manuscript in this journal.
The editorial policy of the journal allows authors and encourages manuscript accommodation online (i.e. in storage of an institution or on the personal websites) as before submission of the manuscript to the editorial office, and during its editorial processing because it contributes to productive scientific discussion and positively affects the efficiency and dynamics of the published manuscript citation (see The Effect of Open Access).











